

February 27, 2025

BSE Limited Listing Department- Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 Scrip Code: 544292	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400051 Symbol: ONESOURCE
---	--

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

Ref: Change in Board of Directors

Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to update the changes in board of directors, as under:

The Board of Directors at their meeting held on Thursday, February 27, 2025 have approved/ noted the following changes in directorship.

Appointment of Directors

1. Appointment of **Ms. Debarati Sen** (DIN 07521172) as an Additional Director (Non-Executive, Independent) w.e.f February 27, 2025 for a period of five years, not liable to retire by rotation, subject to the approval of the shareholders
2. Appointment of **Dr. Claudio Albrecht** (DIN: 10109819) as an Additional Director (Non-Executive, Independent), w.e.f February 27, 2025, for a period of five years, not liable to retire by rotation, subject to the approval of the shareholders.
3. Appointment of **Mr. Vijay Paul Karwal** (DIN: 10905781) as an Additional Director (Non-Executive, Independent) w.e.f February 27, 2025 for a period of five years, not liable to retire by rotation, subject to the approval of the shareholders.

The details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as **Annexure I**.

Cessation of Directorship

The following Directors have stepped down from the position of Directorship of the Company w.e.f February 27, 2025:

1. Dr. Gopakumar Gopalan Nair (DIN: 00092637) as a Non-Executive Independent Director;
2. Ms. Rajashri Santosh Kumar Ojha (DIN: 07058128), as a Non-Executive Independent Director;
3. Mr. Mahadevan Narayanamoni (DIN: 07128788), as a Non-Executive Director and
4. Mr. Bhushan Sudhir Bopardikar (DIN: 09089555), as a Non-Executive Director.

The details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as **Annexure II**. Additional Information in case of resignation of an Independent Director (Schedule III - Para A(7B) of Part A of SEBI LODR) are enclosed as **Annexure III**.

A copy of resignation letters received from the Directors is attached as an **Annexure IV** to this letter. They have confirmed that there are no other material reasons for their resignation:

Board Meeting commenced at 17:15 hrs IST and ended at 18:00 hrs IST.

We request you to take the above on record.

For and on behalf of
OneSource Specialty Pharma Limited

A. Trisha

Digitally signed by
A. Trisha
Date: 2025.02.27
18:25:51 +05'30'

Trisha A
Company Secretary and Compliance Officer
Membership Number: **A47635**

Annexure I

Sl. No.	Particulars	Name of the Directors		
		Ms. Debarati Sen	Dr. Claudio Albrecht	Mr. Vijay Paul Karwal
1.	Reason for change viz. appointment/ re-appointment/ resignation/ removal/ death or otherwise	Appointment of Ms. Debarati Sen (DIN: 07521172) as Additional Director of the Company under the category of Non-Executive Independent Director, effective February 27, 2025, for a period of five years, not liable to retire by rotation, subject to Shareholders' approval.	Appointment of Dr. Claudio Albrecht (DIN: 10109819) as Additional Director of the Company under the category of Non-Executive Independent Director, effective February 27, 2025, for a period of five years, not liable to retire by rotation, subject to Shareholders' approval.	Mr. Vijay Paul Karwal (DIN: 10905781) as Additional Director of the Company under the category of Non-Executive Independent Director, effective February 27, 2025, for a period of five years, not liable to retire by rotation, subject to Shareholders' approval.
2.	Date of appointment/ re-appointment / cessation (as applicable) & term of appointment/ re-appointment	Effective February 27, 2025, for a period of five years, not liable to retire by rotation, subject to Shareholders' approval.	Effective February 27, 2025, for a period of five years, not liable to retire by rotation, subject to Shareholders' approval.	Effective February 27, 2025, for a period of five years, not liable to retire by rotation, subject to Shareholders' approval.
3.	Brief profile (in case of appointment)	Enclosed	Enclosed	Enclosed
4.	Disclosure of relationships between directors (in case of appointment of a director)	None	None	None

5	Disclosures as per NSE/CML/2018/24 dated June 20,2018 and BSE Circular BSE circular no. LIST/COMP/14/2018-19, dated June 20, 2018.	Ms. Debarati Sen is not debarred from holding the office of Director pursuant to any SEBI Order or any other statutory authority.	Dr. Claudio Albrecht is not debarred from holding the office of Director pursuant to any SEBI Order or any other statutory authority.	Mr. Vijay Paul Karwal is not debarred from holding the office of Director pursuant to any SEBI Order or any other statutory authority.
---	--	---	---	--



Dr. Claudio Albrecht

Claudio Albrecht, co-founder and managing partner of Albrecht, Prock & Partners was until August 31st, 2018 CEO of the publicly listed STADA AG. Before this assignment Claudio worked in and with the Generic industry for more than 30 years.

Claudio started his pharmaceutical career at Sandoz in 1987 in Austria and became General Manager of its generic businesses in the Netherlands, in Germany and the USA, before leaving to become CEO of the Ratiopharm Group in 2000. In his time as CEO of the Ratiopharm Group he was driving the internationalization process of the German drug maker beyond Europe and was material for the initiation of the development, manufacturing and commercialization project of Ratiopharm's Biosimilars program. Ratiopharm was first to market with the Biosimilar Filgrastim in Europe.

In 2007 Claudio founded together with Peter Prock the strategy consulting firm CoMeth in Slovakia before he was asked to assume the role of CEO and Chairman of the Board of the Actavis Group. Actavis was operating in over 50 countries worldwide with standalone 2012 revenues in excess of € 2billion.

Under his leadership, Actavis was sold to Watson for 6 bio US\$, which represented an above average industry multiple. As CEO of Actavis Claudio initiated a total turn around process and started a joint venture for the development and commercialization of recombinant Insulin and its Analogues with the objective to build the first Generic "one stop shop" in Diabetes. After the divestiture of Actavis, Claudio founded with Peter Prock the Zug/Switzerland based Albrecht, Prock & Partners AG. Together with Private Equity and strategic investors AP&P worked on numerous acquisition projects amongst which the take private initiative for STADA AG was the most significant. STADA AG was the largest leveraged buyout of a German listed company ever.

Claudio holds a PhD in law.

DEBARATI SEN: Brief Bio:

Ms. Debarati Sen is a highly accomplished global business leader with experience driving transformative business performance through operating and financial expertise. She is currently the Group President for HMTX Industries, a global luxury vinyl tile flooring manufacturer. Ms. Sen has accelerated growth across diversified industrial and consumer businesses, spearheaded turnarounds, strategic M&A and partnerships, and built deep and diverse teams internationally. Most recently Ms. Sen led the largest division in 3M's Consumer Business Group with household brands such as Filtrete™ filters, Command™ hanging solutions and ScotchBlue™ tapes, a profitable portfolio of brands totaling \$2.8 billion in annual sales. Previously as the president of 3M's heritage business of Industrial Abrasives, she led the strategy for robotics and automation redefining prior boundaries in the metal fabrication industry and has been in demand as a speaker in diversified industrials and industrial automation forums. As the CEO and Managing Director, she also led 3M India Ltd. (NSE/BSE - 3MINDIA), 3M Co's public entity in India from June of 2016 to June of 2019.

As Treasurer and Trustee of the Women's Foundation of Minnesota, Ms. Sen leads the Financial Leadership Committee of that organization. She is also currently serving on the Senior Advisory Board of the Global Women's Network, Carlson School of Management, University of Minnesota. She has a bachelor's degree in Electronics from Maulana Azad National Institute of Technology in Bhopal, India and an MBA in Marketing and Finance from XLRI Jamshedpur in India. She has also been inducted into the Fortune India, Most Powerful Women list in 2018 and won the Business Standard Star MNC of the Year award in 2017.

Vijay Karwal: Bio

Vijay Karwal is a Managing Director of CBC Group, based in Singapore, with over 25 years of global management and advisory experience in the healthcare industry, including an extensive background in strategy, business development, M&A and capital raising gained in roles in industry and as a senior investment banker. Headquartered in Singapore, CBC Group is Asia's largest healthcare-dedicated asset management firm, with an AUM of US\$9 billion. With a diversified, multi-product strategy, CBC Group is focused on platform-building, buyout, private credit and royalties, and real estate investments, across the healthcare space, including in pharmaceuticals, biotech, medical technology, and healthcare services. In his role at CBC, Vijay advises on sourcing and execution of investment opportunities as well as portfolio management with particular focus on CBC's credit strategy RBF funds, and regional Southeast Asia coverage for the firm.

He also serves as an Independent Director of Mega Lifesciences PCL, one of the largest pharmaceutical groups in Southeast Asia, stock exchange listed and headquartered in Bangkok, Thailand, and as a Non Executive Director of AffaMed Therapeutics Ltd. and AffaMed Technologies, the joint venture between AffaMed Therapeutics and SIFI SpA, a leading international ophthalmology company headquartered in Italy, to develop, manufacture and commercialize premium Intra Ocular Lenses in the Greater China market.

Vijay was previously an Operating Partner of CBC in which capacity he served as Executive Director and CEO of AffaMed Therapeutics, a Shanghai headquartered CBC portfolio company developing innovative solutions for ophthalmic disorders which he first joined as CFO. He joined CBC from Nomura International in Hong Kong, where he served as Managing Director and Head of Healthcare Investment Banking for the Asia (ex-Japan) region. Prior to Nomura, he was Chief Development Officer, Asia Pacific, as well as General Manager of China operations for DaVita Inc., the NYSE-listed global provider of kidney care services. Vijay previously held several senior investment banking roles globally, including as Co-Head of M&A at CIMB Investment Bank, Asia Pacific Head of Consumer, Retail & Healthcare coverage at RBS, Head of Healthcare Banking in North America at ABN AMRO and RBS, and as a senior member of ABN AMRO Rothschild - the global equity capital markets joint venture between the Rothschild and ABN AMRO groups. Throughout his career he has been involved in a wide variety of advisory and financing transactions in the healthcare sector representing over \$95 billion in transaction value, gaining extensive global experience across postings in London, Chicago, New York, Hong Kong and Singapore.

A native of the Netherlands, Vijay was educated at the University of Southampton, UK, and the University of Groningen, the Netherlands, holds a M.Sc. in Economics, and is also a CFA charter holder.

Annexure II

1. **Cessation of Directorship:** Dr. Gopakumar Gopalan Nair (DIN: 00092637), as a Non-Executive Independent Director

Sr. No	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	Resignation due to personal reasons.
2.	Date of Cessation	February 27, 2025
3.	Term of appointment	N.A.
4.	Brief profile (in case of appointment)	N.A.
5.	Disclosure of relationships between directors (in case of appointment of Director)	N.A.

2. **Cessation of Directorship:** Ms. Rajashri Santosh Kumar Ojha (DIN: 07058128), as a Non-Executive Independent Director

Sr. No	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	Resignation due to personal reasons.
2.	Date of Cessation	February 27, 2025
3.	Term of appointment	N.A.
4.	Brief profile (in case of appointment)	N.A.
5.	Disclosure of relationships between directors (in case of appointment of Director)	N.A.

3. **Cessation of Directorship:** Mr. Mahadevan Narayanamoni (DIN: 07128788), as a Non-Executive Director

Sr. No	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	Resignation due to other professional commitments
2.	Date of Cessation	February 27, 2025
3.	Term of appointment	N.A.
4.	Brief profile (in case of appointment)	N.A.
5.	Disclosure of relationships between directors (in case of appointment of Director)	N.A.

4. **Cessation of Directorship:** Mr. Bhushan Sudhir Bopardikar (DIN: 09089555), as a Non-Executive Director

Sr. No	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	Resignation due to other professional commitments.
2.	Date of Cessation	February 27, 2025
3.	Term of appointment	N.A.
4.	Brief profile (in case of appointment)	N.A.
5.	Disclosure of relationships between directors (in case of appointment of Director)	N.A.

Annexure III

Sl. No.	Particulars	Name of the Directors	
		Dr. Gopakumar Gopalan Nair	Ms. Rajashri Santosh Kumar Ojha
1.	Letter of Resignation along with detailed reason for resignation	Enclosed as Annexure IV	Enclosed as Annexure IV
2.	Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any	<p>A. As a Director in the following Listed entities: Nil</p> <p>B. As a Member in the Committees: Nil</p>	<p>A. As a Director in the following Listed entities: Nil</p> <p>B. As a Member in the Committees: Nil</p>
3.	The independent director shall, along with the detailed reasons, also provide a confirmation that there is no other material reasons other than those provided.	Dr. Gopakumar Gopalan Nair has confirmed that there are no material reasons for his resignation other than those mentioned in the resignation letter.	Ms. Rajashri Santosh Kumar Ojha has confirmed that there are no material reasons for her resignation other than those mentioned in the resignation letter.

Date: February 27, 2025

**The Board of Directors
OneSource Specialty Pharma Limited**

Dear Sir/ Madam,

Re: Resignation from the Directorship of OneSource Specialty Pharma Limited

I hereby tender my resignation as a Non-Executive Director of OneSource Specialty Pharma Limited due to other professional commitments, with effect from the close of business hours on February 27, 2025.

I take this opportunity to thank the Board of Directors and the Management of the Company for their support during my association with the Company.

Warm regards



Bhushan Bopardikar



Dr. Gopakumar G. Nair

M.Sc. Ph. D. LL.M

Date: February 27, 2025

**The Board of Directors
OneSource Specialty Pharma Limited**

Dear Sir/ Madam,

**Re: Resignation from the Directorship of OneSource
Specialty Pharma Limited**

I hereby tender my resignation as an Independent Director of OneSource Specialty Pharma Limited due to my personal reasons, with effect from the close of business hours on February 27, 2025.

I hereby confirm that there is no reason other than the one mentioned above for my resignation.

I take this opportunity to express my sincere gratitude to the Board of Directors and the Management of the Company for their support and cooperation during my tenure.

Warm regards

Gopakumar Gopalan Nair

Office : #333, 3rd Floor, "V-Mall", Asha Nagar, Near Sai Dham, Thakur Complex, Kandivli (East), Mumbai – 400 101

Tel : 40895454 / 49614201 **E-mail :** gopanair@gnaipr.net

Residence : C-002/003, "Gokul Plaza", Thakur Complex, Kandivli (E), Mumbai – 400 101. India. Tel : 022-40106950

Date: February 27, 2025

**The Board of Directors
OneSource Specialty Pharma Limited**


Dear Sir/ Madam,

Re: Resignation from the Directorship of OneSource Specialty Pharma Limited

I hereby tender my resignation as a Non-Executive Director of OneSource Specialty Pharma Limited due to other professional commitments, with effect from the close of business hours on February 27, 2025.

I take this opportunity to thank the Board of Directors and the Management of the Company for their support during my association with the Company.

Warm regards,



Mahadevan Narayanamoni

Date: February 27, 2025

**The Board of Directors
OneSource Specialty Pharma Limited**

Dear Sir/ Madam,

Re: Resignation from the Directorship of OneSource Specialty Pharma Limited

I hereby tender my resignation as an Independent Director of OneSource Specialty Pharma Limited due to my personal reasons, with effect from the close of business hours on February 27, 2025.

I hereby confirm that there is no reason other than the one mentioned above for my resignation.

I take this opportunity to express my sincere gratitude to the Board of Directors and the Management of the Company for their support and cooperation during my tenure.

Warm regards

A handwritten signature in blue ink, appearing to read 'Rajashri Ojha', with a horizontal line drawn through it.

Rajashri Ojha